重性抑郁障碍的脑与血液生物标志物:系统综述
该系统综述整合重性抑郁障碍(MDD)脑与血液的组学研究,发现744个差异表达基因和544个差异甲基化基因在脑与血液中变化方向一致,其中分别有43个和34个与GWAS鉴定的MDD风险位点重叠,并汇聚于发育、炎症、转录、凋亡和线粒体通路。
要点
- 脑与血液中744个差异表达基因方向一致,43个与GWAS风险位点重叠。
- 脑与血液中544个差异甲基化基因方向一致,34个与GWAS风险位点重叠。
- 差异基因汇聚于神经发育、线粒体、神经炎症、凋亡和转录调控通路。
核心结论
- 尽管各研究和脑区中单个失调基因高度可变,但汇聚通路和枢纽基因功能在多项研究中一致出现。
- 需要涉及研究不足脑区的细胞类型特异性多组学研究,以更好理解MDD病理生理并识别生物标志物和治疗靶点。
研究设计与样本
- 系统综述,检索PubMed、Embase和Web of Science。
- 纳入标准:使用人类生物标本、报告MDD与对照的差异表达或差异甲基化基因、使用RNA测序或甲基化谱分析。
- 共纳入54篇文章(30篇脑、20篇血液、4篇两者兼有)。
主要发现
- 744个差异表达基因在脑与血液中变化方向一致,其中43个与GWAS鉴定的MDD风险位点重叠。
- 544个差异甲基化基因在脑与血液中变化方向一致,其中34个与GWAS鉴定的MDD风险位点重叠。
- 多个枢纽基因汇聚于发育、炎症、转录、凋亡和线粒体通路。
关键数值与推荐
- MDD为多基因疾病,GWAS已报告数千个微小效应变异。
- MDD存在显著表观遗传成分,反映基因-环境交互在发病机制中的作用。
- 目前尚无MDD生物标志物或基于精准医学的治疗。
临床怎么用
- 脑与血液中方向一致的差异表达和差异甲基化基因及汇聚通路,可能有助于识别MDD表型特异性生物标志物和治疗靶点。
局限性
- 各研究和脑区中单个失调基因高度可变。
- 需要涉及研究不足脑区的细胞类型特异性多组学研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Major depressive disorder (MDD) is a debilitating neuropsychiatric disease associated with high risk of death by suicide. MDD is heterogeneous, and genome-wide association studies (GWASs) have established that MDD is polygenic, reporting thousands of small-effect variants. There is a significant epigenetic component in MDD, reflecting the role of gene-environment interactions in its pathogenesis. No biomarkers or precision-medicine based treatments exist. Understanding brain methylome and gene expression profiles at the regional and cellular level and whether brain molecular pathways alterations are reflected in blood could help identify phenotype-specific biomarkers and treatment targets for MDD. OBJECTIVES: To integrate and reanalyze findings from bulk and single-nuclei omics of MDD and to determine whether they reveal overlapping brain and blood dysregulated pathways that may inform biomarker and therapeutic targets discovery. EVIDENCE REVIEW: Omic studies in MDD brain and blood were reviewed using PubMed, Embase, and Web of Science. Articles were included if they used human biospecimens, reported differentially expressed or methylated genes when comparing MDD with control, and used RNA sequencing or methylation profiling. In addition, bulk and single nucleus differentially expressed genes were compared with the NHGRI-EBI GWAS Catalog of MDD-associated gene variants. FINDINGS: In the 54 articles included (30 in brain, 20 in blood, and 4 in both), 744 differentially expressed genes were altered in the same direction in brain and blood across studies, 43 of which overlapped with GWAS-identified MDD risk loci. A total of 544 differentially methylated genes were altered in the same direction in brain and blood across studies, 34 of which overlapped with GWAS-identified MDD risk loci. Several hub genes converged on developmental, inflammatory, transcriptional, apoptotic, and mitochondrial pathways. CONCLUSIONS AND RELEVANCE: While the individual dysregulated genes are highly variable across studies and brain regions, converging pathways and hub gene functions, including those related to neurodevelopment, mitochondria, neuroinflammation, apoptosis, and transcriptional regulation emerge across studies. Cell-type specific multiomic studies involving understudied brain regions are needed to better understand the pathophysiology of MDD and identify relevant biomarkers and treatment targets.
引用
- Zallar LJ, Dupont MB. Brain and Blood Biomarkers of Major Depressive Disorder: A Systematic Review. JAMA Psychiatry. 2026. PMID: 41739484. doi:10.1001/jamapsychiatry.2025.4613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。